This is a multi-center, non-interventional study to assess and describe course and outcomes in patients diagnosed with Idiopathic Pulmonary Fibrosis (IPF) who are treated with Esbriet (pirfenidone) in Canada, by measuring and reporting observed predicted forced vital capacity (FVC) change from baseline on an ongoing basis.
Inclusion Criteria:
Exclusion Criteria:
Vancouver, British Columbia V6Z 1Y6, Canada
London, Ontario N6C 2R5, Canada
Toronto, Ontario M5G 2C4, Canada